98-27080. New Animal Drugs For Use In Animal Feeds; Ivermectin  

  • [Federal Register Volume 63, Number 196 (Friday, October 9, 1998)]
    [Rules and Regulations]
    [Pages 54352-54353]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-27080]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Parts 556 and 558
    
    
    New Animal Drugs For Use In Animal Feeds; Ivermectin
    
    AGENCY:  Food and Drug Administration, HHS.
    
    ACTION:  Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY:  The Food and Drug Administration (FDA) is amending the animal 
    drug regulations to reflect approval of a supplemental new animal drug 
    application (NADA) filed by Merial Ltd. The supplemental NADA provides 
    for use of ivermectin Type A medicated articles to make Type B and C 
    medicated swine feeds, to make Type C feed for treatment and control of 
    threadworms (Strongyloides ransomi), and as top-dressing for individual 
    treatment of adult swine.
    
    EFFECTIVE DATE:  October 9, 1998.
    
    FOR FURTHER INFORMATION CONTACT:  Estella Z. Jones, Center for 
    Veterinary Medicine (HFV-135), Food and Drug Administration, 7500 
    Standish Pl., Rockville, MD 20855, 301-594-1643.
    
    SUPPLEMENTARY INFORMATION:  Merial Ltd., 2100 Ronson Rd., Iselin, NJ 
    08830-3077, is sponsor of NADA 140-974 that provides for use of Ivomec 
    (ivermectin 0.6%) Type A articles to make ivermectin Type B and C swine 
    feeds. The Type C feeds contain 1.8 grams ivermectin per ton for 
    feeding to weaned, growing and finishing swine, and adult and breeding 
    swine. It is used for treatment and control of gastrointestinal 
    roundworm, kidney worm, and lungworm infections, and lice and mite 
    infestations. The supplemental NADA provides for use of the Type C 
    feeds for treatment and control of threadworms (Strongyloides ransomi) 
    infections, specifically treatment and control of ``threadworms 
    (Strongyloides ransomi, adults and somatic larvae, and prevention of 
    transmission of infective larvae to piglets, via the colostrum or milk, 
    when fed during gestation),'' and for use as top-dressing for 
    individual treatment of adult swine. The supplemental NADA is approved 
    as of August 10, 1998, and the regulations are amended in Sec. 558.300 
    (21 CFR 558.300) to reflect the approval. The basis of approval is 
    discussed in the freedom of information summary.
        In addition, Sec. 558.300 is amended by redesignating paragraph (c) 
    as paragraph (d), adding new paragraph (c), and in newly redesignated 
    paragraph (d) inserting several editorial and technical changes and 
    adding a required limitation statement.
        This supplemental NADA is for use of approved ivermectin Type A 
    medicated articles to make Type B and C medicated feeds. Ivermectin is 
    a Category II drug as defined in 21 CFR 558.3(b)(1)(ii). As provided in 
    21 CFR 558.4(b), an approved medicated feed application is required for 
    making Type B or C medicated feeds as in this application. Under 
    section 512(m) of the Federal Food, Drug, and Cosmetic Act as amended 
    by the Animal Drug Availability Act of 1996 (Pub. L. 104-250), 
    medicated feed applications have been replaced by the requirement for 
    feed mill licenses. Therefore, use of ivermectin Type A medicated 
    articles to make Type B and C medicated feeds as provided in this NADA 
    is limited to manufacture in a licensed feed mill.
        Also, the regulation concerning tolerances for ivermectin residues 
    in edible tissues is amended to provide for an acceptable daily intake 
    (ADI) for total ivermectin residues. The ADI is the amount of total 
    drug residue that can be safely consumed by humans every day. 
    Previously, FDA had codified safe concentrations for drug residues. The 
    safe concentrations were confusing because few individuals understood 
    the relationship between safe concentrations, a value representing 
    total residues, and tolerances, the part of the drug residue in a given 
    tissue that is detected by a specific analytical method. To eliminate 
    this confusion, FDA is codifying the ADI.
        In addition, the regulations for tolerances for ivermectin residues 
    is further amended to establish a tolerance for ivermectin residues in 
    swine muscle.
        In accordance with the freedom of information provisions of 21 CFR 
    part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
    data and information submitted to support approval of this supplemental 
    application may be seen in the Dockets Management Branch (HFA-305), 
    Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, 
    MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
        Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and 
    Cosmetic Act, this supplemental approval qualifies for 3 years of 
    marketing exclusivity beginning August 10, 1998, because the 
    supplemental application contains substantial evidence of the 
    effectiveness of the drug involved, any studies of animal safety or, in 
    the case of food-producing animals, human food safety studies (other 
    than bioequivalence or residue studies) required for approval of the 
    supplement and conducted or sponsored by the applicant. The 3 years of 
    marketing exclusivity applies only to use in swine for treatment and 
    control of threadworms (Strongyloides ransomi, adults and somatic 
    larvae, and prevention of transmission of infective larvae to piglets, 
    via the colostrum or milk, when fed during gestation).
        FDA has determined under 21 CFR 25.33(a)(1) and (a)(7) that this 
    action is of a type that does not individually or cumulatively have a 
    significant effect on the human environment. Therefore, neither an 
    environmental assessment nor an environmental impact statement is 
    required.
    
    List of Subjects
    
     21 CFR Part 556
    
         Animal drugs, Foods.
    
    21 CFR Part 558
    
         Animal drugs, Animal feeds.
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs and 
    redelegated to the Center for Veterinary Medicine, 21 CFR parts 556 and 
    558 are amended as follows:
    
    PART 556--TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
    
        1. The authority citation for 21 CFR part 556 continues to read as 
    follows:
    
        Authority:  21 U.S.C. 342, 360b, 371.
    
        2. Section 556.344 is revised to read as follows:
    
    
    Sec. 556.344   Ivermectin.
    
        (a) Acceptable daily intake (ADI). The ADI for total residues of 
    ivermectin is 1 microgram per kilogram of body weight per day.
        (b) Tolerances--(1) Liver. A tolerance is established for 22,23-
    dihydroavermectin B1a (marker residue) in liver (target 
    tissue) as follows:
        (i) Cattle. 100 parts per billion.
    
    [[Page 54353]]
    
        (ii) Swine. 20 parts per billion.
        (iii) Sheep. 30 parts per billion.
        (iv) Reindeer. 15 parts per billion.
        (v) American bison. 15 parts per billion.
        (2) Muscle. Muscle residues are not indicative of the safety of 
    other edible tissues. A tolerance is established for 22,23-
    dihydroavermectin B1a (marker residue) in muscle as follows:
        (i) Swine. 20 parts per billion.
        (ii) [Reserved]
    
    PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
    
        3. The authority citation for 21 CFR part 558 continues to read as 
    follows:
    
        Authority:  21 U.S.C. 360b, 371.
    
        4. Section 558.300 is amended by redesignating paragraph (c) as 
    paragraph (d), by adding new paragraph (c) and reserving it, by adding 
    introductory text to newly redesignated paragraph (d), and by revising 
    newly redesignated paragraph (d)(1), to read as follows:
    
    
    Sec. 558.300   Ivermectin.
    
    * * * * *
        (c) [Reserved]
        (d) Conditions of use. It is used in swine feed as follows:
        (1) Amount per ton. For weaned, growing-finishing swine, feed 1.8 
    grams of ivermectin (to provide 0.1 milligram per kilogram of body 
    weight per day). For adult and breeding swine, feed 1.8 to 11.8 grams 
    of ivermectin (to provide 0.1 milligram per kilogram of body weight per 
    day). For adult and breeding swine, may be top-dressed on daily ration 
    for individual treatment at levels of 18.2 to 1180 grams (to provide 
    0.1 milligram per kilogram of body weight per day).
        (i) Indications for use. For treatment and control of 
    gastrointestinal roundworms (Ascaris suum, adults and fourth-stage 
    larvae; Ascarops strongylina, adults; Hyostrongylus rubidus, adults and 
    fourth-stage larvae; Oesophagostomum spp., adults and fourth-stage 
    larvae); kidneyworms (Stephanurus dentatus, adults and fourth-stage 
    larvae); lungworms (Metastrongylus spp., adults); threadworms 
    (Strongyloides ransomi, adults and somatic larvae, and prevention of 
    transmission of infective larvae to piglets, via the colostrum or milk, 
    when fed during gestation); lice (Haematopinus suis); and mange mites 
    (Sarcoptes scabiei var. suis).
        (ii) Limitations. For use in swine feed only. Feed as sole ration 
    for 7 consecutive days. Withdraw 5 days before slaughter. Consult your 
    veterinarian for assistance in the diagnosis, treatment, and control of 
    parasitism.
    * * * * *
    
        Dated: September 28, 1998.
     Margaret Ann Miller,
     Acting Director, Office of New Animal Drug Evaluation, Center for 
    Veterinary Medicine.
    [FR Doc. 98-27080 Filed 10-8-98; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Effective Date:
10/9/1998
Published:
10/09/1998
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
98-27080
Dates:
October 9, 1998.
Pages:
54352-54353 (2 pages)
PDF File:
98-27080.pdf
CFR: (2)
21 CFR 556.344
21 CFR 558.300